Charles River Laboratories International, Inc. $CRL Shares Sold by Gabelli Funds LLC

Gabelli Funds LLC cut its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 90.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,700 shares of the medical research company’s stock after selling 16,800 shares during the quarter. Gabelli Funds LLC’s holdings in Charles River Laboratories International were worth $339,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in CRL. Massachusetts Financial Services Co. MA purchased a new position in Charles River Laboratories International during the fourth quarter worth about $176,478,000. Ameriprise Financial Inc. lifted its position in Charles River Laboratories International by 1,491.1% during the third quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock worth $96,005,000 after buying an additional 575,039 shares during the period. National Bank of Canada FI lifted its position in Charles River Laboratories International by 117.7% during the third quarter. National Bank of Canada FI now owns 946,769 shares of the medical research company’s stock worth $148,131,000 after buying an additional 511,901 shares during the period. Balyasny Asset Management L.P. lifted its position in Charles River Laboratories International by 722.5% during the second quarter. Balyasny Asset Management L.P. now owns 434,226 shares of the medical research company’s stock worth $65,885,000 after buying an additional 381,432 shares during the period. Finally, LSV Asset Management lifted its position in Charles River Laboratories International by 1,773.0% during the third quarter. LSV Asset Management now owns 297,800 shares of the medical research company’s stock worth $46,594,000 after buying an additional 281,900 shares during the period. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL opened at $160.76 on Monday. The company has a market cap of $7.74 billion, a P/E ratio of -42.76, a PEG ratio of 1.83 and a beta of 1.44. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. Charles River Laboratories International, Inc. has a one year low of $132.58 and a one year high of $228.88. The business’s 50-day simple moving average is $167.61 and its 200 day simple moving average is $181.35.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, beating the consensus estimate of $1.96 by $0.10. The business had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The company’s revenue was up 1.2% on a year-over-year basis. During the same period last year, the business posted $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, sell-side analysts forecast that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on CRL shares. TD Cowen reduced their target price on Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, February 20th. UBS Group raised their price objective on Charles River Laboratories International from $170.00 to $175.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Royal Bank Of Canada assumed coverage on Charles River Laboratories International in a report on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 price objective on the stock. Evercore restated an “outperform” rating and issued a $220.00 price objective on shares of Charles River Laboratories International in a report on Friday, May 8th. Finally, Weiss Ratings downgraded Charles River Laboratories International from a “sell (d)” rating to a “sell (e+)” rating in a report on Monday, May 11th. Ten investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $207.69.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.